{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody+Mediated+Rejection&page=2",
    "query": {
      "condition": "Antibody Mediated Rejection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody+Mediated+Rejection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:50:17.067Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03916822",
      "title": "Cell-based Assays for Antibody-mediated Transplant Rejection",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Antibody-Mediated Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Alloantigen-specific B-cells",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Plexision",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2019-04-15",
      "completion_date": "2021-08-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-23",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Charleston, South Carolina",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03916822"
    },
    {
      "nct_id": "NCT06990711",
      "title": "A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antibody Mediated Rejection of Lung Transplant"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-06",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Saint Lake City, Utah",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Saint Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06990711"
    },
    {
      "nct_id": "NCT03744910",
      "title": "Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Physiologic saline solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 194,
      "start_date": "2019-10-14",
      "completion_date": "2024-04-08",
      "has_results": true,
      "last_update_posted_date": "2025-07-23",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03744910"
    },
    {
      "nct_id": "NCT01848301",
      "title": "Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiac Allograft Vasculopathy",
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Optical Coherence Tomography",
          "type": "DEVICE"
        },
        {
          "name": "Acetylcholine",
          "type": "DRUG"
        },
        {
          "name": "Brachial Artery Flow Mediated Dilation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Gladwin, Mark, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-09",
      "completion_date": "2017-05-01",
      "has_results": false,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848301"
    },
    {
      "nct_id": "NCT01147302",
      "title": "A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "C1 Esterase Inhibitor (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2011-08-24",
      "completion_date": "2013-06-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147302"
    },
    {
      "nct_id": "NCT05456243",
      "title": "Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose adipose tissue derived mesenchymal stromal cells (A-MSC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2023-01-30",
      "completion_date": "2026-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05456243"
    },
    {
      "nct_id": "NCT03221842",
      "title": "Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-11-06",
      "completion_date": "2021-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221842"
    },
    {
      "nct_id": "NCT03380936",
      "title": "Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        },
        {
          "name": "Plasma Exchange and IVIG (Intravenous Immunoglobulin )",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-17",
      "completion_date": "2019-10-16",
      "has_results": false,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380936"
    },
    {
      "nct_id": "NCT01399593",
      "title": "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2011-11-02",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399593"
    },
    {
      "nct_id": "NCT03380962",
      "title": "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "End-Stage Renal Disease",
        "Transplant Glomerulopathy",
        "Transplant;Failure,Kidney",
        "Kidney Transplant Failure and Rejection",
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-02-27",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-07-22T07:50:17.067Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380962"
    }
  ]
}